Log in
Enquire now
‌

US Patent 10323037 Aminopyridazinone compounds as protein kinase inhibitors

Patent 10323037 was granted and assigned to Jiangsu Hengrui Medicine on June, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
‌
Jiangsu Hengrui Medicine
Current Assignee
‌
Jiangsu Hengrui Medicine
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10323037
Patent Inventor Names
Qiyue Hu0
Dong Liu0
Minsheng Zhang0
Date of Patent
June 18, 2019
Patent Application Number
15906934
Date Filed
February 27, 2018
Patent Citations Received
‌
US Patent 10626116 Crystalline form of BTK kinase inhibitor and preparation method thereof
Patent Primary Examiner
‌
Emily A Bernhardt
Patent abstract

The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10323037 Aminopyridazinone compounds as protein kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.